Online citations, reference lists, and bibliographies.

“Essential” Phospholipids Versus Nicotinic Acid In The Treatment Of Patients With Type IIb Hyperlipoproteinemia And Ischemic Heart Disease

Anatoli N. Klimov, V. B. Konstantinov, B. Lipovetsky, Alexander S. Kuznetsov, V. Lozovsky, V. Trufanov, S. Plavinsky, Karl-Josef Gundermann, R. Schumacher
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
SummaryIn patients with moderate, dietary noncorrigible hyperlipoproteinemia type IIb and ischemic heart disease, treatment with nicotinic acid is limited by the side effects of the drug. In 100 patients, 6-month treatment with nicotinic acid (n=50) or “essential” phospholipids (EPL); Lipostabil®, manufacturer: Rhône-Poulenc Rorer) (n=50) indicated comparable efficacy for both substances: Significant (p<.001) reductions of serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride values were similar in both groups, while nicotinic acid increased high-density lipoprotein (HDL) cholesterol significantly (p<.01) better than Lipostabil. A detailed analysis of ultracentrifugal lipoprotein profiles, hydroperoxide concentrations in LDL, and cholesterol-accepting properties of HDL in a small number of Lipostabil- and nicotinic acid-treated patients revealed favorable shifts in the lipoprotein profile, significant (p<.05) reductions of LDL hydroperoxides, and favorable increases of the most antiatherogenic HDL2b subfraction only in the Lipostabil-treated group. Clinically, both medications reduced the intensity and number of angina pectoris attacks per week (p<.05), but only Lipostabil-treated patients significantly (p<.05) increased their working capacity in the veloergometric test. Since in the nicotinic acid-treated group dropouts (nine patients, eight related to the drug) and side effects [14] exceeded those in the Lipostabil-treated group (two dropouts not related to the drug, no side effects), it is suggested that Lipostabil is a preferable alternative in the treatment of patients with moderate, dietary noncorrigible hyperlipoproteinemia IIb and ischemic heart disease.
This paper references



This paper is referenced by
10.1080/00958970802146049
Synthesis, spectral properties, crystal structures and biological activity of copper(II) pyridinecarboxylates with N -heterocyclic ligands
P. Segl'a (2008)
10.1111/asj.12832
Improving effect of dietary soybean phospholipids supplement on hepatic and serum indexes relevant to fatty liver hemorrhagic syndrome in laying hens.
F. Yang (2017)
Dietary Modulation of the Dynamics between Leukocyte Inflammation, Cholesterol Flux, and HDL function in Metabolic Syndrome
Catherine J Andersen (2013)
10.1002/14651858.CD009744.pub2
Niacin for primary and secondary prevention of cardiovascular events.
S. Schandelmaier (2017)
10.3390/nu7095372
Bioactive Egg Components and Inflammation
Catherine J Andersen (2015)
10.1111/j.1524-4725.2008.34128.x
Tissue‐Toxic Effects of Phosphatidylcholine/Deoxycholate after Subcutaneous Injection for Fat Dissolution in Rats and a Human Volunteer
S. Schuller-Petrovic (2008)
10.1016/J.TCA.2004.03.016
Correlation of thermal and spectral properties of zinc(II) complexes of pyridinecarboxylic acids with their crystal structures
Z. Vargová (2004)
10.1007/s11745-013-3780-8
Egg Consumption Modulates HDL Lipid Composition and Increases the Cholesterol-Accepting Capacity of Serum in Metabolic Syndrome
Catherine J. Andersen (2013)
10.3168/jds.2018-15240
Symposium review: Milk fat globule size: Practical implications and metabolic regulation.
N. Argov-Argaman (2019)
10.4103/0973-3930.26859
Effect of essentiale in diabetic subjects with Non - Effect of essentiale in diabetic subjects with Non - Alcoholic fatty liver
S. Poongothai (2005)
Phosphatidylcholine in the treatment of localized fat.
D. Hexsel (2003)
10.4327/jsnfs.72.247
Regulation of Lipid Metabolism with Dietary Phospholipids
Bungo Shirouchi (2019)
10.1186/1476-511X-11-3
Health effects of dietary phospholipids
Daniela Küllenberg (2011)
10.1093/ajcn/nqz348
Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries.
M. Dehghan (2020)
Lipodissolve for body sculpting: safety, effectiveness, and patient satisfaction.
Khalid Mahmud (2012)
10.1371/journal.pone.0209565
Changes in lipid droplets morphometric features in mammary epithelial cells upon exposure to non-esterified free fatty acids compared with VLDL
R. Mesilati-Stahy (2018)
10.1007/978-3-540-69518-9_7
Mesotherapy and Injectable Lipolysis
A. Rotunda (2007)
10.1371/journal.pone.0082399
Dietary Omega-3 Polyunsaturated Fatty Acids Alter the Fatty Acid Composition of Hepatic and Plasma Bioactive Lipids in C57BL/6 Mice: A Lipidomic Approach
K. A. Balogun (2013)
10.1097/MOL.0b013e3282ffaf96
Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease
J. Cohn (2008)
10.1111/j.1524-4725.2009.01130.x
Randomized Double‐Blind Clinical Trial of Subcutaneously Injected Deoxycholate Versus a Phosphatidylcholine‐Deoxycholate Combination for the Reduction of Submental Fat
A. Rotunda (2009)
Semantic Scholar Logo Some data provided by SemanticScholar